Skip to main content
Sign In

Christopher Lieu, M.D.

Assistant Professor, Division of Medical Oncology

Lieu     Christopher Lieu, MD


Current Positions
Director, Gastrointestinal Medical Oncology

Deputy Associate Director for Clinical Research

Fellowship Training
University of Texas MD Anderson Cancer Center

Residency Training
University of Colorado

Medical Schools
MD, Wake Forest University School of Medicine

Undergraduate Schools
BS, University of North Carolina–Chapel Hill


Dr. Lieu joined the University of Colorado School of Medicine faculty as an Assistant Professor of Medicine in July 2011.  He trained in internal medicine at the University of Colorado, where he also served as a Chief Medical Resident.  He completed his fellowship training in medical oncology at the University of Texas MD Anderson Cancer Center and served as the Chief Medical Oncology Fellow in 2010.  He currently serves as the Director of GI Medical Oncology at the University of Colorado Cancer Center, is a member of the National Cancer Institute Colon Cancer Task Force, and serves on the National Comprehensive Cancer Network (NCCN) Panel for Neuroendocrine Cancers.

Dr. Lieu is a member of the Developmental Therapeutics (phase I clinical trials) and Gastrointestinal (GI) Medical Oncology Program.   These comprehensive programs include multidisciplinary cancer clinics, tumor boards, and research endeavors.  Dr. Lieu is interested in resistance mechanisms to targeted therapy in GI cancers, and he was awarded the Conquer Cancer Foundation Career Development Award and a NIH K23 grant to study targeted therapies in colorectal cancer.  Dr. Lieu is also investigating novel therapeutic strategies to more effectively treat and prevent colorectal cancer in young adults.

Honors and Awards

      Arnold P. Gold Foundation Excellence in Humanism and Teaching Award

Ruth L. Kirschstein National Research Service Award

American Society of Clinical Oncology (ASCO) Young Investigators Award

Conquer Cancer Foundation Merit Award

Paul Calabresi Career Development Award for Clinical Oncology (K12)

Delegate, ASCO/AACR Methods in Clinical Cancer Research

SWOG Young Investigator Award

ASCO Conquer Cancer Foundation Career Development Award

Department of Internal Medicine Rising Stars Award

Delegate, ASCO Leadership Development Program

NCI Cancer Clinical Investigator Team Leadership Award (CCITLA)

Selected Publications

  1. Lieu C, Janssen WJ, Saint S, Dhaliwal G.  The tip of the iceberg.  J Hosp Med 2009; 4(5):317-20. PMID: 19504498​ 

  2. O’Bryant C, Lieu C**, Leong S, Boinpally R, Basche M, Gore L, Leonardi K, Schultz MK, Hariharan S, Chow L, Diab S, Gibbs A, Eckhardt SG. A dose-ranging study of the pharmacokinetics and pharmacodynamics of the selective apoptotic antineoplastic drug (SAAND), OSI-461, in patients with advanced cancer, in the fasted and fed state. Cancer Chemother Pharmacol 2009; 63(3):477-89. PMID: 18509645

  3. Lieu C, Chow L, Pierson A, Eckhardt SG, O’Bryant CL, Morrow M, Tran ZV, Wright JJ, Gore L. A phase I study of bortezomib, etoposide and carboplatin in patients with advanced solid tumors refractory to standard therapy. Invest New Drugs 2009; 27(1):53-62. PMID: 18618082
  4. Kopetz S, Hoff PM, Morris JS, Wolff RA, Eng C, Adinin R, Overman MJ, Valero V, Wen S, Lieu C, Yan S, Tran HT, Ellis L, Abbruzzese JL, Heymach JV.  Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance. J Clin Oncol 2010; 28(3):453-9. PMID: 20008624

  5. Lieu C, Kopetz S.  Src family of protein kinases: a new and promising target for colorectal cancer.  Clin Colorectal Cancer 2010; 9(2):89-94. PMID: 20378502
  6. Tran B, Kopetz S, Tie J, Gibbs P, Jiang ZQ, Lieu CH, Agarwal A, Maru DM, Sieber O, Desai J.  Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer.  Cancer 2011: 117(20):4623-32. PMID: 21456008
  7. Lieu CH, Lambert LA, Wolff RA, Eng C, Zhang N, Wen S, Rafeeq S, Taggart M, Fournier K, Royal R, Mansfield P, Overman MJ.  Systemic chemotherapy and surgical cytoreduction for poorly differentiated and signet ring cell adenocarcinomas of the appendix.  Ann Oncol 2011; 23(3): 652-8.  PMID: 21653683

  8. Lieu CH, Heymach JV, Overman MJ, Tran H, Kopetz S.  Beyond VEGF: Inhibition of the Fibroblast Growth Factor Pathway and Antiangiogenesis.  Clin Cancer Res 2011; 17(19): 6130-9.  PMID: 21953501

  9. Scott AJ, Leong S, Messersmith WA, Lieu CH.  A Moving Target: challenges in treating BRAF-mutant colorectal cancer.  Colorectal Cancer 2013; 2(3): 197-204.

  10. Lieu CH, Tan AC, Leong S, Diamond JR, Eckhardt SG.  From Bench to Bedside: Examples of lessons learned in the translation of preclinical studies of targeted agents in cancer drug development.  J Nat Cancer Inst 2013; 105(19): 1441-56.  PMID: 24052618

  11. Lieu CH, Tran H, Jiang ZQ, Mao M, Overman MJ, Lin E, Eng C, Morris J, Ellis L, Heymach JV, Kopetz S.  The association of alternate VEGF ligands with resistance to anti-VEGF therapy in metastatic colorectal cancer.  PLOS ONE 2013; 8(10):e77117.  PMID: 24143206

  12. Lieu CH, Renfro LA, de Gramont A, Meyers JP, Maughan TS, Seymour MT, Goldberg RM, Sargent D, Eckhardt SG, Eng, C.  The association of age with survival in patients with metastatic colorectal cancer: Analysis from the ARCAD Clinical Trials Program.  J Clin Oncol 2014; 32(27): 2975-84. PMID 25002720

  13. Brittain P, Eckhardt SG, Lieu CH. Potential Role of MEK Inhibition in Treating Patients with Colorectal Cancer. Current Cancer Therapy Reviews 2014; 10(1):34-38.

  14. Chen ZY, Raghav K, Lieu CH, Jiang ZQ, Eng C, Vauthey JN, Chang GJ, Quao W, Morris J, Hong D, Hoff P, Tran H, Menter DG, Heymach J, Overman M, Kopetz S.  Cytokine profile and prognostic significance of high neutrophil-lymphocyte ratio in colorectal cancer.  Br J Cancer 2015; doi. 10.1038/bjc.2015.61 [epub ahead of print].  PMID 25688736.

  15. Arcaroli JJ, Tai WM, McWilliams R, Bagby S, Blatchford PJ, Varella-Garcia M, Purkey A, Quackenbush KS, Song EK, Pitts TM, Gao D, Lieu CH, McManus M, Tan AC, Zheng X, Ozeck M, Olson P, Jiang ZQ, Kopetz S, Jimeno A, Keysar S, Eckhardt SG, Messersmth WA.  A NOTCH1 Gene Copy Number Gain is a Prognostic Indicator of Worse Survival and a Predictive Biomarker to a Notch1 Targeting Antibody in Colorectal Cancer.  Int J Cancer 2015; 138(1): 195-205. PMID: 26152787

  16. Tai D, Wells K, Arcaroli J, Vanderbilt C, Aisner DL, Messersmith WA, Lieu CH.  Targeting the WNT signaling pathway in cancer therapeutics.  The Oncologist 2015; 20(10):1189-98. PMID: 26306903.  PMCID: PMC4591954

  17. Lieu CH, Klauck PJ, Henthorn PK, Tentler JJ, Tan AC, Spreafico A, Selby HM, Britt BC, Bagby SM, Arcaroli JJ, Messersmith WA, Pitts TM, Eckhardt SG.  Antitumor activity of a potent MEK inhibitor, TAK-733, against colorectal cancer cell lines and patient derived xenografts.  Oncotarget 2015.  doi: 10.18632/oncotarget.5949  PMID: 26439693

  18. Kessler ER, Eckhardt SG, Pitts TM, Bradshaw-Pierce EL, O'byrant CL, Messersmith WA, Nallapreddy S, Weekes C, Spratlin J, Lieu CH, Kane MA, Eppers S, Freas E, Leong S. Phase I trial of vandetanib in combination with gemcitabine and capecitabine in patients with advanced solid tumors with an expanded cohort in pancreatic and biliary cancers. Invest New Drugs. 2015 Dec 30. PMID: 26715573.

  19. Weekes CD, Lamberts LE, Borad MJ, Voortman J, McWilliams RR, Diamond JR, de Vries EG, Verheul HM, Lieu CH, Kim GP, Want Y, Scales SJ, Samineni D, Brunstein F, Choi Y, Maslyar DJ, Colon-Otero G.  Phase I Study of DMOT4039A, an Antibody-Drug Conjugate Targeting Mesothelin, in Patients with Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer.  Mol Cancer Ther 2016; 15(3):439-47.  PMID: 26823490

  20. Meguid C, Schulick RD, Schefter TE, Lieu CH, Boniface M, Williams N, Vogel JD, Gajdos C, McCarter M, Edil BH.  The Multidisciplinary Approach to GI Cancer Results in Change of Diagnosis and Management of Patients. Multidisciplinary Care Impacts Diagnosis and Management of Patients. Ann Surg Onc 2016; doi: 10.1245/s10434-016-5343-8. PMID: 27342825

  21. Scott A, Lieu CH, Messersmith WA.  Therapeutic approaches to RAS mutation.  Cancer J. 2016; 22(3): 165-74.  PMID: 27341593

  22. Friedrich T, Leong S, Lieu CH, Beyond RAS and BRAF: A target rich disease that is ripe for picking.  J Gastronintest Oncol 2016; 7(5) 705-712. ISSN: 2219-679

  23. Chapman BC, Hosokawa P, Henderson W, Paniccia A, OVerbey DM, Messersmith W, Lieu C, Stiegmann GV, Schulick RD, Gajdos C. Impact of neoadjuvant chemoradiation on perioperative outcomes in patients with rectal cancer. J Surg Oncol 2017 Mar 23. doi: 10.1002/jso.24613.  PMID: 28334436

  24. Stumpf PK, Amini A, Jones BL, Koshy M, Sher DJ, Lieu CH, Schefter TE, Goodman KA, Rusthoven CG. Adjuvant radiotherapy improves overall survival in resected gastric adenocarcinoma: a National Cancer Database analysis. Cancer 2017. Doi: 10.1002/cncr.30748.  PMID: 28513823

  25. Lieu CH, Hildalgo M, Berlin JD, Ko AH, Cervantes A, LoRusso P, Gerber DE, Eder JP, Eckhardt SG, Kapp AV, Tsuhako A, McCall B, Pirzkall A, Uyei A, Tabernero J. A Phase Ib Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Cobimetinib and Duligotuzumab in Patients with Previously Treated Locally Advanced or Metastatic Cancers with Mutant KRAS. Oncologist 2017; doi: 10.1634/theoncologist.2017-0175. PMID: 28592615



NIH K12 Paul Calabresi Career Development Award for Clinical Oncology

ASCO Cancer Foundation Young Investigators Award

Conquer Cancer Foundation Career Development Award

Cancer League of Colorado Research Award

Hope Foundation SWOG Early Exploration and Development (SEED) Award

NIH K23 CA190849-01A1​ ​​​​​​